Hemophagocytic lymphohistiocytosis secondary to T-cell/histiocyte-rich large B-cell lymphoma

Katherine Devitt a, Jan Cerny b, Bradley Switzer b, Muthalagu Ramanathan b, Rajneesh Nath b, Hongbo Yu a, Bruce A. Woda a, Benjamin J. Chen a,⁎

a Department of Pathology UMass Memorial Medical Center and University of Massachusetts Medical School, 1 Innovation Drive, Biotech 3, Worcester, MA 01605, USA
b Department of Hematology/Oncology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA 01605, USA

A R T I C L E  I N F O

Article history:
Received 11 April 2014
Accepted 19 May 2014
Available online 2 June 2014

Keywords:
Hemophagocytic lymphohistiocytosis (HLH)
T-cell/histiocyte rich large B-cell lymphoma (THRLBCL)
Chemotherapy
Stem cell transplant

A B S T R A C T

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening clinical syndrome characterized by dysregulation of the immune system. Impaired function of cytotoxic T cells and natural killer cells is often seen, and T-cell malignancies represent most cases of lymphoma-associated HLH. HLH associated with B-cell lymphoma is rare. We describe a case of a 30-year-old man who presented with fever, splenomegaly, and hyperferritinemia. Bone marrow biopsy revealed T-cell/histiocyte-rich large B-cell lymphoma, a rare, aggressive B-cell malignancy. This case highlights the interplay between a pro-inflammatory cytokine microenvironment and tumor-mediated immune suppression, and addresses the importance of accurately diagnosing these entities for appropriate clinical management.

© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

1. Introduction

Hemophagocytic lymphohistiocytosis (HLH) is an uncommon, hyperinflammatory syndrome that is often fatal when treatment is delayed [1]. Diagnosis may be difficult due to the wide range of symptoms associated with HLH and lack of specific diagnostic tests. Genetic causes of familial HLH relate to defects in cytotoxic granule exocytosis or function, whereas the acquired or secondary form is often associated with infection, malignancy, or autoimmune/immunodeficiency conditions. Defects in cytotoxic T cells and natural killer (NK) cells are seen in nearly all cases of HLH [1]. Hematologic neoplasms account for the majority of malignancy-associated HLH, and T-cell malignancies predominate. HLH associated with underlying B-cell lymphoma is rare, and seems to occur in older patients with a low incidence of marrow involvement by lymphoma [2]. Here, we describe a case of HLH arising in a young patient with diffuse marrow involvement by T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL), a subtype representing 1–3% of diffuse large B-cell lymphomas (DLBCL) with a characteristic background of cytotoxic T cells and histiocytes.

2. Clinical presentation

A 30-year-old male with a past medical history of adult-onset Still’s disease diagnosed 1.5 years ago was transferred from an outside hospital with fever, jaundice, weight loss, and impending respiratory failure. On physical exam, there was splenomegaly and imaging demonstrated retroperitoneal lymphadenopathy and pulmonary infiltrates. Lab findings revealed pancytopenia and liver function tests were suggestive of severe hepatitis. Significant laboratory findings included total bilirubin 10.2 mg/dL (reference range 0.3–1.2 mg/dL), alkaline phosphatase 410 IU/L (30–115 IU/L); AST 320 IU/L (10–41 IU/L), ALT 476 IU/L (10–40 IU/L), LDH 749 IU/L (110–240 IU/L), ferritin 14,298 ng/mL (23–336 ng/mL); WBC 2100/μL (4300–11,500/μL); hemoglobin 7.5 g/dL (14.0–18.0 g/dL), and platelet count 68,000/μL (140,000–440,000/μL). An extensive infectious disease workup did not reveal an etiology. Concern for hemophagocytic lymphohistiocytosis was raised and a bone marrow biopsy was performed.

3. Pathologic findings

Bone marrow aspirate smears were hemodilute but notable for frequent macrophages exhibiting erythro- and leukophagocytosis (Fig. 1A). Bone biopsy demonstrated abnormal hematopoiesis and diffuse infiltration by lymphocytes and histiocytes (Fig. 1B). CD20 highlighted scattered, large atypical cells (Fig. 1C) that were negative...
for CD15 and CD30. The background infiltrate was composed predominantly of T cells with a cytotoxic phenotype (CD3+, CD5+, CD7+, CD8+, and TIA-1+ [Fig. 2]), with admixed CD68+ histiocytes (Fig. 2D). Flow cytometry analysis did not show evidence of an abnormal B- or T-cell population. Polymerase chain reaction studies did not detect clonal IgH, IgK or TCR gene rearrangements, although neoplastic cells were scant. In situ hybridization for Epstein Barr virus (EBV)-encoded RNA was negative.

A diagnosis of hemophagocytic lymphohistiocytosis arising in a background of T-cell/histiocyte-rich large B-cell lymphoma was made.
5. Discussion

Recent studies of genetic HLH have shed light on the pathophysiology of the disease. Defects in cytotoxic pathways of T cells and NK cells are thought to lead to an inability to clear antigenic stimuli, resulting in a “cytokine storm” and perpetuation of the inflammatory response [1]. Unchecked macrophage activation, hemophagocytosis, and tissue infiltration ensue.

Acquired HLH is most often associated with infections (49%), of which EBV is the most common, followed by malignancies (27%), rheumatologic disorders (7%) and immune deficiency syndromes (6%) [1]. Still’s disease, also known as systemic-onset juvenile idiopathic arthritis, is a form of juvenile rheumatoid arthritis that carries an overall risk of HLH of 10% [6]. In our particular case, the relationship between the patient’s hematologic malignancy and underlying autoimmune disorder, diagnosed as adult-onset Still’s disease, is unclear.

When HLH is associated with malignancy, T- and NK-cell leukemias/lymphomas predominate, although HLH has also been seen with anaplastic large cell lymphoma, other leukemias, and solid tumors. HLH association with non-Hodgkin B-cell lymphoma is relatively rare, involving predominantly older patients (> 60 years), with sparing of the bone marrow, as compared with T- or NK-cell lymphomas [2].

T-cell/histiocyte-rich large B cell lymphoma accounts for 1–3% of DLBCL, presents more commonly in males with a median age of 30 years, and typically pursues an aggressive clinical course. Diagnosis is based on the identification of < 10% large neoplastic B cells in a background of cytotoxic T cells and histiocytes [7]. Immunohistochemistry can assist with differentiation from nodular lymphocyte-predominant Hodgkin lymphoma and lymphocyte-rich classical Hodgkin lymphoma by demonstrating expression of pan-B cell markers and absence of CD15 and CD30 in large cells, along with a cytokotic phenotype of the background lymphocytes. Molecular analysis for IGH@/IGK@ gene rearrangements can assist in demonstrating clonality; however, the paucity of neoplastic cells in THRLBCL can diminish the sensitivity of this PCR based assay leading to false-negative results [8].

From a pathophysiological standpoint, it is of interest that HLH arose in the setting of THRLBCL in this patient. Although THRLBCL is a B-cell malignancy, it is unique in that the predominant cell population consists of cytotoxic T cells and histiocytes. Recent gene expression profiling studies have suggested that the tumor microenvironment of THRLBCL in fact favors a tolerogenic host immune response despite the abundance of apparently ineffective cytotoxic T cells [9]. In addition, both the tumor cells as well as the infiltrating histiocytes have been shown to express the immune suppressive molecule PD-L1, presumably as a mechanism for tumor immune evasion, representing a potential target for therapy [10]. Interestingly, in 1999, Mitterer, et al. [11], reported one other case of HLH-associated THRLBCL, which was associated with reactivated EBV infection, again raising the possibility that the overall host immune environment contributes to disease manifestation. Further studies examining the interplay between systemic immune hyperactivation, tumor-mediated immune suppression, and autoimmunity in cases of malignancy-associated HLH are warranted to uncover novel and directed therapeutic approaches.

References

[1] Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br J Haematol 2013;161:609–22.
[2] Han A, Lee HR, Park B, et al. Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol 2007 493–8.
Henter J, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124–31.

Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood 2009;118:4041–52.

Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002;99:2685–93.

Kelly A, Ramanan AV. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheum 2007;19:477–81.

De Wolf-Peeters C, Delabie J, Campo E, et al. T cell/histiocyte-rich large B-cell lymphoma. In: Swerdlow SH, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed.. Lyon: IARC Press; 2008. p. 238–9.

van Dongen JJM, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 2003;17:2257–317.

Van Loo P, Tousseyn T, Vanhentenrijk V, et al. T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. Haematologica 2010;95:440–8.

Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013;19:3462–73.

Mitterer M, Pescosta N, McQuain C, et al. Epstein-Barr virus related hemophagocytic syndrome in a T-cell rich B-cell lymphoma. Ann Oncol 1999;10:231–4.